Adding ForeseeHome to your home monitoring plan has been shown to help 94% of people who progressed from dry to wet age-related macular degeneration (AMD) preserve good vision. Preserving good vision allows you to continue to drive, read, and remain independent.

94% of patients using ForeseeHome maintained driving vision (20/40 or better)
at wet AMD diagnosis compared with 62% of patients using standard methods of detection alone.

  • Office visits triggered by using ForeseeHome as part of a home monitoring plan were 16 times more likely to catch new cases of wet AMD compared with regularly scheduled doctor visits in a large clinical trial
  • ForeseeHome is more sensitive to changes in AMD than older home testing methods like the Amsler grid. Patients preserved more of their vision when wet AMD was detected using ForeseeHome than waiting for a regular eye exam. Adding ForeseeHome gives you a better chance of preserving good vision and remaining independent

Learn more about how ForeseeHome works

ForeseeHome is not appropriate for all patients. If you have difficulty using a mouse or have other issues with your eyes, ForeseeHome may not be right for you. If this is the case, talk to your doctor about other at-home monitoring options to protect your vision.

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD.